In his 2014 budget request, President Obama requested a 16% increase for the National Center for Advancing Translational Research, but only a 1.5% increase for the NIH overall. So why the emphasis on translation research?
We speak with pharmacology researcher Sean Ekins, GlaxoSmithKline vice president Pearl Huang, and NCATS director Chris Austin why the time for translation research is now and about the challenges that remain.
Also, in our science round table with science writers Sarah C.P. Williams and Ashley Yeager, we discuss what the Glowing Plant Kickstarter project means for the future of science funding and synthetic biology.
|Featured in This Episode|
|Sean Ekins is vice president of science at Collaborative Drug Discovery, Inc. and adjunct professor and the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill.|
|Pearl Huang is vice president and global head of the Discovery Partnerships with Academia program at GlaxoSmithKline.|
|Chris Austin is the director of the Center for Advancing Translational Sciences.|
|Sarah C.P. Williams is a freelance science writer based out of Kailua, Hawaii. You can follow her latest work at http://www.facebook.com/sarahcpwilliams.
|Ashley Yeager works in the Office of News and Communications at Duke University and is also a freelance science writer. You can follow her at https://plus.google.com/104786459743651414888/about.
|Andrew S. Wiecek is news editor at BioTechniques and host of the monthly podcast BenchTalk.You can follow him at http://www.biotechniques.com/news.|
|Episode Notes & Links|
Sean Ekins Interview
Chris Austin Interview
Science Rountable Notes
Antibody Validation | BenchTalk November 2013
Epigenetics Sept 2013 V2
The Translation Research Emphasis | BenchTalk, Episode 14
Behind the Scenes of GE's Cell Imaging Contest | BenchTalk, Episode 13
The Rise in Droplet PCR | BenchTalk, Episode 12
AGBT13 Round-Up: Advances in Genome Biology and Technology | BenchTalk, Episode 11 New York, NY